# Osprey Pharmaceuticals USA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osprey-pharmaceuticals-usa

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.ospreypharma.com
- Total disclosed funding: $17M
- Latest round: Series A (May 19, 2009)
- Investors on record: 6

## About

Osprey Pharmaceuticals USA focuses on the acquisition and sale of premium domain names, enhancing online presence for businesses and entrepreneurs through strategic digital asset transactions.Founded in 2008 in San Francisco, US, Osprey Pharmaceuticals USA specializes in premium domain name acquisition and sales. The company has successfully closed four deals, with the latest Series A funding round completed in May 2009, raising USD 6.20 mn from multiple investors including BDC Capital and Novo Nordisk A/S. The company is led by CEO Nicky DiCicco, with founders Michael Baughan and Stephen Jakob bringing prior entrepreneurial experience to the firm.Osprey Pharma specializes in the acquisition and sale of premium domain names, serving businesses and entrepreneurs aiming to establish or improve their online presence. The company offers a platform for listing domain names, allowing clients to purchase outright or make offers. Its global customer base targets companies seeking digital assets to enhance brand identity and market reach.Osprey Pharma generates revenue through the sale of domain names, employing a transaction structure that includes direct sales and negotiation options for buyers. Revenue is primarily derived from one-time purchases, with pricing standardized for flagship domain offerings, and ancillary services like transaction support to ensure smooth transfers.The company plans to leverage its recent Series A funding of USD 6.20 mn, completed in May 2009, to enhance its offerings and expand its market reach. Osprey Pharmaceuticals USA is targeting growth into new geographic regions and expanding its portfolio of domain names, aiming to cater to businesses in emerging markets over the next few years.

## Funding rounds

- Series A, May 19, 2009, $6.2M — Burrill & Company, BDC Capital, Western Technology Investment, Yasuda Enterprise Development, GeneChem, Novo Nordisk A/S
- Series A, Sep 3, 2008, $11M — Burrill & Company, BDC Capital, Western Technology Investment, Yasuda Enterprise Development, GeneChem, Novo Nordisk A/S

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series A
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series A
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series A
- Novo Nordisk A/S — Series A